View Financial HealthShaperon 배당 및 자사주 매입배당 기준 점검 0/6Shaperon 배당금을 지급한 기록이 없습니다.핵심 정보n/a배당 수익률-112.2%자사주 매입 수익률총 주주 수익률-112.2%미래 배당 수익률n/a배당 성장률n/a다음 배당 지급일n/a배당락일n/a주당 배당금n/a배당 성향n/a최근 배당 및 자사주 매입 업데이트업데이트 없음모든 업데이트 보기Recent updatesNew Risk • Jun 25New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of South Korean stocks, typically moving 15% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risks Earnings have declined by 8.7% per year over the past 5 years. Shareholders have been substantially diluted in the past year (53% increase in shares outstanding). Revenue is less than US$1m (₩281m revenue, or US$182k). Minor Risks Share price has been volatile over the past 3 months (15% average weekly change). Market cap is less than US$100m (₩35.1b market cap, or US$22.7m).공고 • Apr 17Shaperon Inc. announced that it has received KRW 8.6 billion in fundingOn April 15, 2026, Shaperon Inc. has closed the transaction.공고 • Apr 09Shaperon Inc. announced that it expects to receive KRW 8.6 billion in fundingShaperon Inc. announces a private placement to issue Series 1 Bearer-type interest-bearing unsecured private placement convertible bonds for gross proceeds of KRW 8,600,000,000 on April 7, 2026. Expected closing date of the offering is April 15, 2026. Interest rate of the Notes is 0% and Maturity of the Bonds is April 15, 2031. Conversion price is KRW 1,685. Conversion period starts from April 15, 2027 and ends on March 15, 2031. GVA Coven-14 General Private Investment Trust advised by Samsung Securities Co., Ltd. for KRW 800,000,000, GVA Coven-0 General Private Investment Trust advised by Samsung Securities Co., Ltd for KRW 750,000,000.공고 • Mar 12Shaperon Inc., Annual General Meeting, Mar 27, 2026Shaperon Inc., Annual General Meeting, Mar 27, 2026, at 10:00 Tokyo Standard Time. Location: conference room, 174-10, jagok-ro, gangnam-gu, seoul South KoreaNew Risk • Nov 22New major risk - Shareholder dilutionThe company's shareholders have been substantially diluted in the past year. Increase in shares outstanding: 53% This is considered a major risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (14% average weekly change). Revenue has declined by 87% over the past year. Shareholders have been substantially diluted in the past year (53% increase in shares outstanding). Revenue is less than US$1m (₩12m revenue, or US$8.0k). Minor Risk Market cap is less than US$100m (₩80.1b market cap, or US$54.5m).공고 • Nov 14Shaperon Inc. Attends 7th Inflammasome Therapeutics Summit in BostonShaperon Inc. announced that it attended the 7th Inflammasome Therapeutics Summit held in Boston, Massachusetts, from November 4-6, 2025. During the event, CEO Dr. Seungyong Seong delivered a keynote presentation highlighting the company's latest clinical and preclinical achievements in the development of inflammasome-modulating therapies for atopic dermatitis and alopecia areata. The Inflammaome Therapeutics Summit is a leading global conference dedicated to advances in inflammasome research and drug development. Shaperon's participation and keynote presentation underscore the growing recognition of its GPCR19-based drug discovery platform as an emerging technology with the potential to reshape the treatment landscape for inflammatory and autoimmune diseases. In his keynote, Dr. Seong presented the company's progress on GPCR19-targeted inflammasome modulation, a novel therapeutic strategy designed to control inflammation at its upstream initiation phase. Unlike conventionalNLRP3 inhibitors that act downstream, Shaperon's approach regulates the formation of the inflammasome complex itself, confirming the broad applicability of its inflammasome-targeted technology. Shaperon's topical candidate NuGel, the world's first GPCR19 agonist for atopic dermatitis, demonstrated positive efficacy and safety results in Phase 2b Part 1 clinical trials. The company also shared new preclinical data across acne, rosacea, and diabetic foot ulcers, confirming the broad applicabilityof its inflammasome- target technology. Shaperon's proprietary AI-powered drug discovery platform integrates multi-parametric modeling to predict target suitability, pharmacokinetic properties and toxicity profiles, enabling faster and more reliable development decisions. One of its AI-derived candidates, Nualeratine, showed a 74% higher hair regrowth rate in preclinical models of autoimmune alopecia compared to competing compounds.공고 • Nov 06Shaperon Inc. has completed a Follow-on Equity Offering in the amount of KRW 24.860387 billion.Shaperon Inc. has completed a Follow-on Equity Offering in the amount of KRW 24.860387 billion. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 16,049,314 Price\Range: KRW 1549 Discount Per Security: KRW 30.98 Transaction Features: Rights Offering공고 • Aug 19Shaperon Inc. has filed a Follow-on Equity Offering in the amount of KRW 30.0426 billion.Shaperon Inc. has filed a Follow-on Equity Offering in the amount of KRW 30.0426 billion. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 16,100,000 Price\Range: KRW 1866 Discount Per Security: KRW 37.32 Transaction Features: Rights OfferingNew Risk • Aug 19New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of South Korean stocks, typically moving 12% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-₩16b free cash flow). Share price has been highly volatile over the past 3 months (12% average weekly change). Revenue has declined by 86% over the past year. Revenue is less than US$1m (₩30m revenue, or US$21k). Minor Risk Market cap is less than US$100m (₩60.9b market cap, or US$43.8m).분석 기사 • Aug 01Is Shaperon (KOSDAQ:378800) In A Good Position To Deliver On Growth Plans?Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...New Risk • May 30New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of South Korean stocks, typically moving 9.4% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-₩17b free cash flow). Revenue has declined by 92% over the past year. Shareholders have been substantially diluted in the past year (31% increase in shares outstanding). Revenue is less than US$1m (₩18m revenue, or US$13k). Minor Risks Share price has been volatile over the past 3 months (9.4% average weekly change). Market cap is less than US$100m (₩114.4b market cap, or US$82.9m).New Risk • Mar 21New major risk - Financial positionThe company has less than a year of cash runway based on its current free cash flow trend. Free cash flow: -₩17b This is considered a major risk. With less than a year's worth of cash, the company will need to raise capital or take on debt unless its cash flows improve. This would dilute existing shareholders or increase balance sheet risk. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-₩17b free cash flow). Share price has been highly volatile over the past 3 months (12% average weekly change). Revenue has declined by 92% over the past year. Shareholders have been substantially diluted in the past year (31% increase in shares outstanding). Revenue is less than US$1m (₩18m revenue, or US$12k). Minor Risk Market cap is less than US$100m (₩97.1b market cap, or US$66.3m).New Risk • Mar 12New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of South Korean stocks, typically moving 12% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (12% average weekly change). Revenue has declined by 36% over the past year. Shareholders have been substantially diluted in the past year (31% increase in shares outstanding). Revenue is less than US$1m (₩91m revenue, or US$63k). Minor Risk Market cap is less than US$100m (₩101.4b market cap, or US$70.0m).공고 • Mar 06Shaperon Inc., Annual General Meeting, Mar 25, 2025Shaperon Inc., Annual General Meeting, Mar 25, 2025, at 10:00 Tokyo Standard Time. Location: auditorium, 419, bongeunsa-ro, gangnam-gu, seoul South KoreaNew Risk • Jan 16New major risk - Shareholder dilutionThe company's shareholders have been substantially diluted in the past year. Increase in shares outstanding: 31% This is considered a major risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (16% average weekly change). Revenue has declined by 36% over the past year. Shareholders have been substantially diluted in the past year (31% increase in shares outstanding). Revenue is less than US$1m (₩91m revenue, or US$63k). Minor Risk Market cap is less than US$100m (₩121.3b market cap, or US$83.2m).분석 기사 • Dec 20Is Shaperon (KOSDAQ:378800) In A Good Position To Deliver On Growth Plans?Just because a business does not make any money, does not mean that the stock will go down. For example, although...분석 기사 • Sep 02We're Keeping An Eye On Shaperon's (KOSDAQ:378800) Cash Burn RateWe can readily understand why investors are attracted to unprofitable companies. For example, although Amazon.com made...New Risk • Jul 08New minor risk - Shareholder dilutionThe company's shareholders have been diluted in the past year. Increase in shares outstanding: 31% This is considered a minor risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (15% average weekly change). Revenue has declined by 84% over the past year. Revenue is less than US$1m (₩215m revenue, or US$156k). Minor Risks Less than 3 years of financial data is available. Shareholders have been diluted in the past year (31% increase in shares outstanding). Market cap is less than US$100m (₩45.3b market cap, or US$32.9m).New Risk • May 29New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of South Korean stocks, typically moving 13% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (13% average weekly change). Revenue has declined by 84% over the past year. Revenue is less than US$1m (₩215m revenue, or US$158k). Minor Risks Less than 3 years of financial data is available. Market cap is less than US$100m (₩52.8b market cap, or US$38.7m).분석 기사 • Apr 12Is Shaperon (KOSDAQ:378800) In A Good Position To Invest In Growth?Just because a business does not make any money, does not mean that the stock will go down. For example, biotech and...New Risk • Apr 12New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of South Korean stocks, typically moving 8.2% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risks Revenue has declined by 89% over the past year. Revenue is less than US$1m (₩215m revenue, or US$156k). Minor Risks Less than 3 years of financial data is available. Share price has been volatile over the past 3 months (8.2% average weekly change). Market cap is less than US$100m (₩66.6b market cap, or US$48.2m).공고 • Mar 20Shaperon Enrolls its First Patient in Phase 2 U.S. Clinical Trial for Atopic Dermatitis Therapy 'Nugel'Shaperon Inc. announced the enrollment of the first patient in the Phase 2 clinical trial for Nugel, its therapy for Atopic Dermatitis. This milestone marks the start of a crucial phase in Shaperon's effort to advance treatment for patients globally. With FDA approval secured for the Global Phase 2 Clinical Trials (IND) of Nugel in September 2023, Shaperon is dedicated to evaluating its efficacy in improving the Eczema Area Severity Index (EASI) across a diverse cohort of 210 patients with mild to moderate atopic dermatitis. Employing a rigorous double-blind, placebo-controlled methodology, the trial is anticipated to conclude by the first half of 2026. Market research forecasts indicate a robust growth of over 8.7%, projecting the global atopic dermatitis market to reach $19.1 billion by 2030. Presently, patients rely on steroids and FDA-approved medications, yet there remains a pressing need for novel drugs due to their adverse effects and limited efficacy. Of particular note, more than 70% of patients exhibit positive responses to the biomarker discovered during Shaperon's phase 2 clinical trials in Korea, categorized as "A type A atopic patients." This treatment, distinguished by its superior safety and efficacy compared to existing JAK inhibitors or PDE4 inhibitors in the market, has garnered attention at U.S. and European forums. Shaperon has already initiated patent applications for this biomarker, enabling tailored treatments for patients showing exceptional responses to Nugel. Nugel represents a paradigm shift in atopic dermatitis therapy as the world's first inflammation control drug targeting 'GPCR19' action. Its unique mechanism of action, exclusive to immune-related cells, offers minimal side effects while effectively addressing inflammatory pathways. Beyond atopic dermatitis, Nugel holds promise for treating a spectrum of skin conditions, further underscoring its potential impact on global healthcare.New Risk • Jul 24New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of South Korean stocks, typically moving 8.0% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk No financial data reported. Minor Risks Share price has been volatile over the past 3 months (8.0% average weekly change). Market cap is less than US$100m (₩114.7b market cap, or US$89.5m).지급의 안정성과 성장배당 데이터 가져오는 중안정적인 배당: 과거에 A378800 의 주당 배당금이 안정적이었는지 판단하기에는 데이터가 부족합니다.배당금 증가: A378800 의 배당금 지급이 증가했는지 판단하기에는 데이터가 부족합니다.배당 수익률 vs 시장Shaperon 배당 수익률 vs 시장A378800의 배당 수익률은 시장과 어떻게 비교되나요?구분배당 수익률회사 (A378800)n/a시장 하위 25% (KR)1.4%시장 상위 25% (KR)4.3%업계 평균 (Biotechs)0.4%분석가 예측 (A378800) (최대 3년)n/a주목할만한 배당금: 회사가 최근 지급을 보고하지 않았기 때문에 하위 25%의 배당금 지급자에 대해 A378800 의 배당 수익률을 평가할 수 없습니다.고배당: 회사가 최근 지급을 보고하지 않았기 때문에 배당금 지급자의 상위 25%에 대해 A378800 의 배당 수익률을 평가할 수 없습니다.주주 대상 이익 배당수익 보장: 배당금 지급이 수익으로 충당되는지 확인하기 위해 A378800 의 지급 비율을 계산하기에는 데이터가 부족합니다.주주 현금 배당현금 흐름 범위: A378800 에서 지급을 보고하지 않았기 때문에 배당 지속 가능성을 계산할 수 없습니다.높은 배당을 제공하는 우량 기업 찾기7D1Y7D1Y7D1YKR 시장에서 배당이 강한 기업.View Management기업 분석 및 재무 데이터 상태데이터최종 업데이트 (UTC 시간)기업 분석2026/08/21 18:54종가2026/08/21 00:00수익2026/03/31연간 수익2025/12/31데이터 소스당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.패키지데이터기간미국 소스 예시 *기업 재무제표10년손익계산서현금흐름표대차대조표SEC 양식 10-KSEC 양식 10-Q분석가 컨센서스 추정치+3년재무 예측분석가 목표주가분석가 리서치 보고서Blue Matrix시장 가격30년주가배당, 분할 및 기타 조치ICE 시장 데이터SEC 양식 S-1지분 구조10년주요 주주내부자 거래SEC 양식 4SEC 양식 13D경영진10년리더십 팀이사회SEC 양식 10-KSEC 양식 DEF 14A주요 개발10년회사 공시SEC 양식 8-K* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.분석 모델 및 스노우플레이크이 보고서를 생성하는 데 사용된 분석 모델의 세부 정보는 당사의 GitHub 페이지에서 확인하실 수 있습니다. 또한 보고서 사용 방법에 대한 가이드와 YouTube 튜토리얼도 제공하고 있습니다.Simply Wall St 분석 모델을 설계하고 구축한 세계적 수준의 팀에 대해 알아보세요.산업 및 섹터 지표산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.분석가 소스Shaperon Inc.는 0명의 분석가가 다루고 있습니다. 이 중 0명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.
New Risk • Jun 25New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of South Korean stocks, typically moving 15% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risks Earnings have declined by 8.7% per year over the past 5 years. Shareholders have been substantially diluted in the past year (53% increase in shares outstanding). Revenue is less than US$1m (₩281m revenue, or US$182k). Minor Risks Share price has been volatile over the past 3 months (15% average weekly change). Market cap is less than US$100m (₩35.1b market cap, or US$22.7m).
공고 • Apr 17Shaperon Inc. announced that it has received KRW 8.6 billion in fundingOn April 15, 2026, Shaperon Inc. has closed the transaction.
공고 • Apr 09Shaperon Inc. announced that it expects to receive KRW 8.6 billion in fundingShaperon Inc. announces a private placement to issue Series 1 Bearer-type interest-bearing unsecured private placement convertible bonds for gross proceeds of KRW 8,600,000,000 on April 7, 2026. Expected closing date of the offering is April 15, 2026. Interest rate of the Notes is 0% and Maturity of the Bonds is April 15, 2031. Conversion price is KRW 1,685. Conversion period starts from April 15, 2027 and ends on March 15, 2031. GVA Coven-14 General Private Investment Trust advised by Samsung Securities Co., Ltd. for KRW 800,000,000, GVA Coven-0 General Private Investment Trust advised by Samsung Securities Co., Ltd for KRW 750,000,000.
공고 • Mar 12Shaperon Inc., Annual General Meeting, Mar 27, 2026Shaperon Inc., Annual General Meeting, Mar 27, 2026, at 10:00 Tokyo Standard Time. Location: conference room, 174-10, jagok-ro, gangnam-gu, seoul South Korea
New Risk • Nov 22New major risk - Shareholder dilutionThe company's shareholders have been substantially diluted in the past year. Increase in shares outstanding: 53% This is considered a major risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (14% average weekly change). Revenue has declined by 87% over the past year. Shareholders have been substantially diluted in the past year (53% increase in shares outstanding). Revenue is less than US$1m (₩12m revenue, or US$8.0k). Minor Risk Market cap is less than US$100m (₩80.1b market cap, or US$54.5m).
공고 • Nov 14Shaperon Inc. Attends 7th Inflammasome Therapeutics Summit in BostonShaperon Inc. announced that it attended the 7th Inflammasome Therapeutics Summit held in Boston, Massachusetts, from November 4-6, 2025. During the event, CEO Dr. Seungyong Seong delivered a keynote presentation highlighting the company's latest clinical and preclinical achievements in the development of inflammasome-modulating therapies for atopic dermatitis and alopecia areata. The Inflammaome Therapeutics Summit is a leading global conference dedicated to advances in inflammasome research and drug development. Shaperon's participation and keynote presentation underscore the growing recognition of its GPCR19-based drug discovery platform as an emerging technology with the potential to reshape the treatment landscape for inflammatory and autoimmune diseases. In his keynote, Dr. Seong presented the company's progress on GPCR19-targeted inflammasome modulation, a novel therapeutic strategy designed to control inflammation at its upstream initiation phase. Unlike conventionalNLRP3 inhibitors that act downstream, Shaperon's approach regulates the formation of the inflammasome complex itself, confirming the broad applicability of its inflammasome-targeted technology. Shaperon's topical candidate NuGel, the world's first GPCR19 agonist for atopic dermatitis, demonstrated positive efficacy and safety results in Phase 2b Part 1 clinical trials. The company also shared new preclinical data across acne, rosacea, and diabetic foot ulcers, confirming the broad applicabilityof its inflammasome- target technology. Shaperon's proprietary AI-powered drug discovery platform integrates multi-parametric modeling to predict target suitability, pharmacokinetic properties and toxicity profiles, enabling faster and more reliable development decisions. One of its AI-derived candidates, Nualeratine, showed a 74% higher hair regrowth rate in preclinical models of autoimmune alopecia compared to competing compounds.
공고 • Nov 06Shaperon Inc. has completed a Follow-on Equity Offering in the amount of KRW 24.860387 billion.Shaperon Inc. has completed a Follow-on Equity Offering in the amount of KRW 24.860387 billion. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 16,049,314 Price\Range: KRW 1549 Discount Per Security: KRW 30.98 Transaction Features: Rights Offering
공고 • Aug 19Shaperon Inc. has filed a Follow-on Equity Offering in the amount of KRW 30.0426 billion.Shaperon Inc. has filed a Follow-on Equity Offering in the amount of KRW 30.0426 billion. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 16,100,000 Price\Range: KRW 1866 Discount Per Security: KRW 37.32 Transaction Features: Rights Offering
New Risk • Aug 19New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of South Korean stocks, typically moving 12% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-₩16b free cash flow). Share price has been highly volatile over the past 3 months (12% average weekly change). Revenue has declined by 86% over the past year. Revenue is less than US$1m (₩30m revenue, or US$21k). Minor Risk Market cap is less than US$100m (₩60.9b market cap, or US$43.8m).
분석 기사 • Aug 01Is Shaperon (KOSDAQ:378800) In A Good Position To Deliver On Growth Plans?Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
New Risk • May 30New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of South Korean stocks, typically moving 9.4% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-₩17b free cash flow). Revenue has declined by 92% over the past year. Shareholders have been substantially diluted in the past year (31% increase in shares outstanding). Revenue is less than US$1m (₩18m revenue, or US$13k). Minor Risks Share price has been volatile over the past 3 months (9.4% average weekly change). Market cap is less than US$100m (₩114.4b market cap, or US$82.9m).
New Risk • Mar 21New major risk - Financial positionThe company has less than a year of cash runway based on its current free cash flow trend. Free cash flow: -₩17b This is considered a major risk. With less than a year's worth of cash, the company will need to raise capital or take on debt unless its cash flows improve. This would dilute existing shareholders or increase balance sheet risk. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-₩17b free cash flow). Share price has been highly volatile over the past 3 months (12% average weekly change). Revenue has declined by 92% over the past year. Shareholders have been substantially diluted in the past year (31% increase in shares outstanding). Revenue is less than US$1m (₩18m revenue, or US$12k). Minor Risk Market cap is less than US$100m (₩97.1b market cap, or US$66.3m).
New Risk • Mar 12New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of South Korean stocks, typically moving 12% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (12% average weekly change). Revenue has declined by 36% over the past year. Shareholders have been substantially diluted in the past year (31% increase in shares outstanding). Revenue is less than US$1m (₩91m revenue, or US$63k). Minor Risk Market cap is less than US$100m (₩101.4b market cap, or US$70.0m).
공고 • Mar 06Shaperon Inc., Annual General Meeting, Mar 25, 2025Shaperon Inc., Annual General Meeting, Mar 25, 2025, at 10:00 Tokyo Standard Time. Location: auditorium, 419, bongeunsa-ro, gangnam-gu, seoul South Korea
New Risk • Jan 16New major risk - Shareholder dilutionThe company's shareholders have been substantially diluted in the past year. Increase in shares outstanding: 31% This is considered a major risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (16% average weekly change). Revenue has declined by 36% over the past year. Shareholders have been substantially diluted in the past year (31% increase in shares outstanding). Revenue is less than US$1m (₩91m revenue, or US$63k). Minor Risk Market cap is less than US$100m (₩121.3b market cap, or US$83.2m).
분석 기사 • Dec 20Is Shaperon (KOSDAQ:378800) In A Good Position To Deliver On Growth Plans?Just because a business does not make any money, does not mean that the stock will go down. For example, although...
분석 기사 • Sep 02We're Keeping An Eye On Shaperon's (KOSDAQ:378800) Cash Burn RateWe can readily understand why investors are attracted to unprofitable companies. For example, although Amazon.com made...
New Risk • Jul 08New minor risk - Shareholder dilutionThe company's shareholders have been diluted in the past year. Increase in shares outstanding: 31% This is considered a minor risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (15% average weekly change). Revenue has declined by 84% over the past year. Revenue is less than US$1m (₩215m revenue, or US$156k). Minor Risks Less than 3 years of financial data is available. Shareholders have been diluted in the past year (31% increase in shares outstanding). Market cap is less than US$100m (₩45.3b market cap, or US$32.9m).
New Risk • May 29New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of South Korean stocks, typically moving 13% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (13% average weekly change). Revenue has declined by 84% over the past year. Revenue is less than US$1m (₩215m revenue, or US$158k). Minor Risks Less than 3 years of financial data is available. Market cap is less than US$100m (₩52.8b market cap, or US$38.7m).
분석 기사 • Apr 12Is Shaperon (KOSDAQ:378800) In A Good Position To Invest In Growth?Just because a business does not make any money, does not mean that the stock will go down. For example, biotech and...
New Risk • Apr 12New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of South Korean stocks, typically moving 8.2% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risks Revenue has declined by 89% over the past year. Revenue is less than US$1m (₩215m revenue, or US$156k). Minor Risks Less than 3 years of financial data is available. Share price has been volatile over the past 3 months (8.2% average weekly change). Market cap is less than US$100m (₩66.6b market cap, or US$48.2m).
공고 • Mar 20Shaperon Enrolls its First Patient in Phase 2 U.S. Clinical Trial for Atopic Dermatitis Therapy 'Nugel'Shaperon Inc. announced the enrollment of the first patient in the Phase 2 clinical trial for Nugel, its therapy for Atopic Dermatitis. This milestone marks the start of a crucial phase in Shaperon's effort to advance treatment for patients globally. With FDA approval secured for the Global Phase 2 Clinical Trials (IND) of Nugel in September 2023, Shaperon is dedicated to evaluating its efficacy in improving the Eczema Area Severity Index (EASI) across a diverse cohort of 210 patients with mild to moderate atopic dermatitis. Employing a rigorous double-blind, placebo-controlled methodology, the trial is anticipated to conclude by the first half of 2026. Market research forecasts indicate a robust growth of over 8.7%, projecting the global atopic dermatitis market to reach $19.1 billion by 2030. Presently, patients rely on steroids and FDA-approved medications, yet there remains a pressing need for novel drugs due to their adverse effects and limited efficacy. Of particular note, more than 70% of patients exhibit positive responses to the biomarker discovered during Shaperon's phase 2 clinical trials in Korea, categorized as "A type A atopic patients." This treatment, distinguished by its superior safety and efficacy compared to existing JAK inhibitors or PDE4 inhibitors in the market, has garnered attention at U.S. and European forums. Shaperon has already initiated patent applications for this biomarker, enabling tailored treatments for patients showing exceptional responses to Nugel. Nugel represents a paradigm shift in atopic dermatitis therapy as the world's first inflammation control drug targeting 'GPCR19' action. Its unique mechanism of action, exclusive to immune-related cells, offers minimal side effects while effectively addressing inflammatory pathways. Beyond atopic dermatitis, Nugel holds promise for treating a spectrum of skin conditions, further underscoring its potential impact on global healthcare.
New Risk • Jul 24New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of South Korean stocks, typically moving 8.0% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk No financial data reported. Minor Risks Share price has been volatile over the past 3 months (8.0% average weekly change). Market cap is less than US$100m (₩114.7b market cap, or US$89.5m).